Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 970 in its research report ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...

Zydus Lifesciences Limited announced a notable 19% increase in revenue for FY25, with net profits rising to Rs. 47,451 mn.

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

The consolidated net profit of Zydus Lifesciences Ltd for the fourth quarter of financial year 2025 dropped marginally to ...

Zydus Lifesciences Limited reported a significant 19% increase in revenue for FY25, reaching Rs. 2,32,415 million. The ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Ahmedabad-based Zydus Lifesciences Ltd has registered a decline of around 1% in net profit at Rs. 1,170.9 crore during the last quarter of FY25, as compared to Rs. 1,182.3 crore in the same period a ...

Zydus Lifesciences posted Q4 profit at Rs 1,170.90 crore, marginally lower than Rs 1182.30 crore recorded during the ...

Results: Zydus Lifesciences Q4FY25 net profit dips 1% to Rs 1,244 crore due to exceptional charge; revenue grows 17% to Rs ...

Consolidated revenue from operations rose 18% YoY to Rs 6528 crore, while EBITDA surged 30% to Rs 2,126 crore, with margins ...